IO Biotech
iobiotech.com
Oncology Therapeutics
Vaccines
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
Read more
Report
IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma
(RTTNews) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & Co Inc.'s (MRK) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the fir
Read more
Report
Report
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline result
Read more
Report
IO Biotech Reports Progress on Cylembio Development and Upcoming FDA Submission Plans
IO Biotech is on track to submit a BLA for Cylembio by 2025, with significant clinical milestones achieved.
Read more
Report
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed -- -- Data P
Read more
Report